Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7501–7550 of 75493
On March 25, 2025, in connection with the Chaintrade transaction, Paul Couture was terminated from his position as Chief Technology Officer of the Company.
John Power, the former President and CEO of the Company resigned as President and CEO
Koby Kushner was appointed to serve as President and CEO of the Company
On March 26, 2025, the board of directors of Southland Holdings, Inc. (the “Company”) appointed Rudy Renda as a Class II director to fill a vacant seat
Mr. Stagno will report to Tim O’Brien, the Company's Chief Financial Officer, who previously served as the Company’s Principal Accounting Officer and Principal Financial Officer and will continue to serve as the Company's Principal Financial Officer.
appointed Christopher Stagno, age 50, as the Company’s Group Vice President, Chief Accounting Officer (Principal Accounting Officer), effective April 21, 2025.
On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.
On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.
On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
Effective March 26, 2025, Gregory J. Hayes was elected to the Board of Directors (the “Board”) of Becton, Dickinson and Company (“BD”).
On March 26, 2025, upon the recommendation of the Governance and Corporate Responsibility Committee of the Board of Directors (the “Board”) of V.F. Corporation (the “Company”), the Board accepted W. Rodney McMullen’s offer of resignation from the Board and reduced the size of the Board to twelve directors, each effective immediately.
On March 27, 2025, National Health Investors, Inc. (the “Company” or “NHI”) announced that, upon the recommendation of its Nominating and Corporate Governance Committee, it has increased the size of the Board to eight members and has appointed Robert W. Chapin, Jr. to fill the newly created seat on the Board, effective immediately.
On March 21, 2025, Dr. Wendye R. Robbins notified the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) that she will not stand for election at the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”) and, accordingly, her term on the Board will expire at and as of the Annual Meeting.
On March 27, 2025, upon the recommendation from Aeva Technologies, Inc. (the “Company”) Nominating and Corporate Governance Committee, the board of directors of the Company (the “Board”) appointed Katherine Motlagh as a Class I director.
On March 27, 2025, Erin L. Polek notified the Board of her decision to resign from the Board and all committees thereof, effective March 31, 2025.
On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.
Santiago Arroyo, M.D., Ph.D., notified the Board of his resignation as the Company's Chief Development Officer, effective March 24, 2025.
On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.
appointed Alessandro Riva, M.D., to the Board and the Scientific Committee of the Board, effective as of the close of business on March 25, 2025, New York City time.
On March 25, 2025, Messrs. Sachse and Duskin informed the Board that they will retire from the Board, effective as of April 2, 2025.
Effective as of April 2, 2025, the Board appointed Mr. Seipel as Chairman of the Board and Mr. Heath as Lead Independent Director of the Board.
On March 25, 2025, the Board appointed each of the New Directors to serve as a member of the Board, effective as of April 2, 2025.
Effective as of April 2, 2025, the Board appointed Mr. Seipel as Chairman of the Board
On March 25, 2025, the Board appointed each of the New Directors to serve as a member of the Board, effective as of April 2, 2025.
On March 25, 2025, Messrs. Sachse and Duskin informed the Board that they will retire from the Board, effective as of April 2, 2025.
On March 24, 2025, Kimberly J. Harris notified the Board of Directors of Ameren Corporation (the "Company") that she was resigning as a director of the Company, effective immediately.
On March 21, 2025, Jessica Buss notified Argo Group International Holdings, Inc. (the “Company”) of her resignation as Chief Executive Officer of the Company, effective immediately
Christopher Donahue, the Company’s Chief Financial Officer, was appointed as the Chief Executive Officer of the Company
David Chan, the Company’s Chief Accounting Officer, was appointed as the Chief Financial Officer of the Company
On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer.
Maria Maccecchini will continue to serve as principal financial officer on an interim basis.
On March 26, 2025, the Board of Directors (the “Board”) of Beta Bionics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Gerard Michel as a Class III director of the Company, with a term of office expiring at the 2028 annual meeting of stockholders.
On March 27, 2025, the Board of Directors (the “Board”) of Wolfspeed, Inc. (the “Company”) appointed Robert Feurle to serve as the Company’s Chief Executive Officer and a member of the Board, effective May 1, 2025
After a transition period, Mr. Werner will continue to serve as a non-employee director and Chairman of the Board.
Effective March 27, 2025, Vineet Agarwal, Chief Financial Officer of Korro Bio, Inc., or the Company, ended his temporary medical leave of absence, which had been in effect since February 11, 2025.
the Company’s Board of Directors appointed Mr. Oliver Dolan, age 42, current Senior Vice President, Finance, to serve as the Company’s principal accounting officer effective March 27, 2025.
Dr. Ram Aiyar, who had been serving as the Company’s interim principal financial officer, is no longer serving in that role as of March 27, 2025 and continues to serve as the Company’s President and Chief Executive Officer (principal executive officer).
On March 24, 2025, Evergy’s Board of Directors elected Mr. Gummig to serve as Vice President, Chief Accounting Officer and principal accounting officer of Evergy, effective April 2, 2025.
Effective March 25, 2025, the Company appointed Fabrice De Bosschère as the Company’s acting Chief Accounting Officer and Principal Accounting Officer, subject to the Board of Director’s formal appointment, effective May 1, 2025.
On March 21, 2025, Kurt Schwarz, Chief Accounting Officer and Principal Accounting Officer of Marcus & Millichap, Inc. (the “Company”) notified the Company of his decision to retire and resign from all of his positions with the Company and its subsidiaries, effective March 24, 2025.
On March 21, 2025, James L. Wieser informed the Board of Directors (the “ Board ”) of Finward Bancorp, an Indiana corporation (the “ Bancorp ”), of his decision to retire as a member of the Board of the Bancorp and its wholly-owned Indiana state-chartered commercial bank subsidiary Peoples Bank (“ Peoples Bank ”), effective as of the conclusion of the Bancorp’s 2025 Annual Meeting of Shareholders.
The employment of Thomas Butler as Chief Executive Officer of the Company ended on March 25, 2025 (the “Effective Date”).
Dr. Hitchcock, a member of the Board, was appointed as the Company’s interim Chief Executive Officer and principal executive officer
On the Effective Date, Mr. Butler resigned as a director and Chairman of the Board
Rainer (Ramses) Erdtmann, the Company’s President, Chief Operating Officer and a member of the Board, was appointed as the Company’s principal financial officer and principal accounting officer
On March 26, 2025, Cathy E. Minehan, a member of the Bright Horizons Family Solutions Inc. (the “Company”) Board of Directors (the “Board”), informed the Board of her intent to retire from the Board, effective June 3, 2025.
On March 24, 2025, Pacific Biosciences of California, Inc. (the “Company”) entered into an offer letter with Jim R. Gibson to serve as its Chief Financial Officer. Mr. Gibson will be appointed as the Company’s Chief Financial Officer and principal financial officer effective as of as his first date of employment, which is anticipated to be March 31, 2025
Christian Henry, the Company’s President and Chief Executive Officer, who has been serving also as the Company’s interim Chief Financial Officer and principal financial officer since December 6, 2024 will cease serving as interim Chief Financial Officer and principal financial officer upon commencement of Mr. Gibson’s employment but will continue serving as the Company’s President and Chief Executive officer.
On March 25, 2025, Chris Terrill notified the board of directors (the “Board”) of Yelp Inc. (the “Company”) of his decision not to stand for reelection to the Board at the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”).
Ellie Fields notified Calix, Inc. (the “Company”) that she would not be standing for re-election to the Board of Directors (“Board”) of the Company upon the expiration of her term at the Company’s upcoming annual meeting of stockholders scheduled to be held on May 8, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.